4-[1-[4-(3,4-Dimethylphenoxy)butyl]benzimidazol-2-yl]-1-prop-2-enylpyrrolidin-2-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 4-[1-[4-(3,4-Dimethylphenoxy)butyl]benzimidazol-2-yl]-1-prop-2-enylpyrrolidin-2-one
• 化学式: C₂₆H₃₁N₃O₂
• 分子量: 417.5
• InChiKey: XNLUDRULBSSUBG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  31
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  47.4
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] NOVEL GLUTAMATE TRANSPORTER ACTIVATORS AND METHODS USING SAME<br/>[FR] NOUVEAUX ACTIVATEURS DE TRANSPORTEURS DE GLUTAMATE ET PROCÉDÉS LES UTILISANT
  申请人：UNIV DREXEL

  公开号：WO2018132829A1

  公开（公告）日：2018-07-19

  The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.

  本发明提供了一种用于治疗、改善或预防由于谷氨酸转运体活性异常降低或中枢神经系统细胞外谷氨酸浓度异常增加而引起、诱导或特征化的疾病或疾病的化合物。在某些实施例中，该化合物刺激谷氨酸转运体。
• Glutamate transporter activators and methods using same
  申请人：DREXEL UNIVERSITY

  公开号：US11377452B2

  公开（公告）日：2022-07-05

  The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.

  本发明提供的化合物可用于治疗、改善或预防由谷氨酸转运体活性异常降低或细胞外中枢神经系统谷氨酸浓度异常升高引起、诱发或表征的疾病或紊乱。在某些实施方案中，化合物可刺激谷氨酸转运体。
• Glutamate Transporter Activators and Methods Using Same
  申请人：Drexel University

  公开号：US20200255445A1

  公开（公告）日：2020-08-13

  The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.
• GLUTAMATE TRANSPORTER ACTIVATORS AND METHODS USING SAME
  申请人：Drexel University

  公开号：US20220402938A1

  公开（公告）日：2022-12-22

  The present invention provides compounds useful for treating, ameliorating or preventing a disease or disorder that is caused, induced or characterized by abnormal reduction in glutamate transporter activity or abnormal increase in extracellular CNS glutamate concentration in a subject. In certain embodiments, the compound stimulates a glutamate transporter.